Bristol-Myers Squibb gets FDA complete response letter for hepatitis C drug daclatasvir
The initial daclatasvir NDA submitted by the company to the FDA focused on the drug’s use in combination with asunaprevir, an NS3/4A protease inhibitor. Given the withdrawal of